Literature DB >> 32089502

[Biologic effects of high doses per fraction].

N Grellier1, Y Belkacemi2.   

Abstract

The radiobiological concepts described for conventional doses per fraction (1.8 to 2Gy) seem difficult to translate to high doses per fraction radiobiology. In fact, specific mechanisms are involved during high dose per fraction irradiation, involving vascular microenvironment damage and anti tumor immune response. The "5R's" of "classical" radiobiology (factors influencing the response of healthy or cancer cells to irradiation) seem to play a less important role in case of high doses per fraction. In addition, applicability of the linear quadratic model in this context is debated. It is therefore difficult to obtain reliable equivalent doses, hence the importance of including our patients in clinical trials, especially in case of concomitant systemic treatments. In addition to stereotactic radiotherapy, flash irradiations defined by a dose rate approximately 2000 times faster than "conventional" irradiation can also deliver high doses per fraction, with a much better tolerance for normal tissue without loss of anti tumor efficacy. Finally, availability of robust prospective data is a prerequisite to answer the question of short and long-term risk/benefit ratio of these different irradiation techniques.
Copyright © 2020 Société française de radiothérapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Ablative radiotherapy; Hypofractionation; Hypofractionnement; Radiobiologie; Radiobiology; Radiochirurgie; Radiosurgery; Radiothérapie ablative

Year:  2020        PMID: 32089502     DOI: 10.1016/j.canrad.2019.06.017

Source DB:  PubMed          Journal:  Cancer Radiother        ISSN: 1278-3218            Impact factor:   1.018


  1 in total

1.  Relationship between biodosimetric parameters and treatment volumes in three types of prostate radiotherapy.

Authors:  Zsuzsa S Kocsis; Tibor Major; Csilla Pesznyák; Dalma Mihály; Gábor Stelczer; Márta Kun-Gazda; Gyöngyi Farkas; Gábor Székely; Péter Ágoston; Kliton Jorgo; László Gesztesi; Csaba Polgár; Zsolt Jurányi
Journal:  Sci Rep       Date:  2021-12-23       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.